
Boehringer eyes H2 drug launches after strong H1 growth
Boehringer Ingelheim is preparing for multiple drug launches in the second half of 2025, following strong first-half financial results that saw the company report a 6.3% rise in group net sales to €14.0 billion ($16 billion). According to the company, H1 …